Introduction {#s1}
============

Hypersensitivity pneumonitis is an interstitial lung disease (ILD) caused by an exaggerated immune response to the inhalation of a wide variety of organic particles in genetically susceptible individuals \[[@C1]--[@C5]\]. The prognosis of acute hypersensitivity pneumonitis is usually favourable; however, chronic fibrotic hypersensitivity pneumonitis often progresses, with the subsequent destruction of the lung architecture \[[@C4], [@C6]\].

The heterogeneous nature of the immune response and the clinical differences through the disease suggest that multiple molecular pathways are involved in the development and progression of the disease.

Previous studies have described the participation of some alleles from the major histocompatibility complex in hypersensitivity pneumonitis susceptibility. Particularly, human leukocyte antigen (HLA) class II alleles were identified in patients with pigeon breeder\'s disease and summer-type hypersensitivity pneumonitis \[[@C7]--[@C9]\], suggesting that genetic factors located inside the HLA region contribute to hypersensitivity pneumonitis development. Class II -*DRB1* and -*DQB1* alleles involved in the 8.1 ancestral haplotype seem to determine the development of specific autoantibodies, both organ-specific and non-organ-specific \[[@C10]\].

In 2016 a cohort of patients with chronic hypersensitivity pneumonitis was examined by A[degunsoye]{.smallcaps} *et al*. \[[@C11]\] to determine the prevalence of autoimmune characteristics. They found that a significant minority of patients with hypersensitivity pneumonitis (15%) displayed autoimmune features and that the presence of autoimmunity was an independent predictor of the increased mortality.

Throughout patient evaluation with hypersensitivity pneumonitis, the presence of circulating autoantibodies is often detected without fulfilling the criteria for a connective tissue disease. To date, it is not known whether this subgroup of hypersensitivity pneumonitis patients has a different genetic susceptibility associated with HLA compared to the autoantibody-negative group.

In this context, this study aimed to examine the allele frequencies of class II HLA alleles to reveal putative differences between hypersensitivity pneumonitis with and without autoantibodies (HPAbs^+^ and HPAbs^−^, respectively) and whether some polymorphisms are associated with mortality rate.

Material and methods {#s2}
====================

Study population {#s2a}
----------------

A retrospective review of adult patients (age ≥18 years) referred to the ILD clinic at the National Institute of Respiratory Diseases (Mexico City, Mexico) was conducted, and samples with enough DNA quality from 170 patients with a confirmed diagnosis of hypersensitivity pneumonitis during the period 2003--2018 were included ([figure 1](#F1){ref-type="fig"}). Since the year 2000, DNA samples for genetic studies are obtained from patients with ILD, with clear explanation, and signed informed consent is duly collected.

![Inclusion of hypersensitivity pneumonitis with and without autoantibodies (HPAbs^+^ and HPAbs**^−^**, respectively), showing exclusion rates for the different analyses. PFT: pulmonary function test.](ERJ-01380-2019.01){#F1}

All patients had at least three prior generations born in Mexico (parents and grandparents) and were considered as Mexican mestizo. We have previously demonstrated that this criterion is a good proxy of Mexican ancestry evaluated by ancestry-informative markers \[[@C12]\].

Hypersensitivity pneumonitis was diagnosed according to previously described criteria \[[@C13], [@C14]\], as follows. 1) Symptoms and pulmonary function tests alterations compatible with ILD; 2) high-resolution computed tomography (HRCT) showing poorly defined nodules, ground-glass attenuation and air trapping in expiration (80% of the HPAbs^+^ and 54% of the HPAbs^−^ also showed alterations compatible with fibrosis, such as irregular linear opacities and traction bronchiectasis and occasionally cystic lesions); 3) bronchoalveolar lavage lymphocytosis \>30%; and 4) biopsy (performed in 30% of the HPAbs^+^ and 28% of the HPAbs^−^) compatible with hypersensitivity pneumonitis. A multidisciplinary team confirmed the diagnosis.

Clinical data were obtained from the medical records. The variables collected included demographical data, comorbidities, tobacco smoking history, environmental antigen exposure assessment, clinical laboratory studies, pulmonary function tests (including forced vital capacity, diffusing capacity of the lung for carbon monoxide (*D*~LCO~) and 6-min walk test) and mortality from all causes at 1-year follow-up.

We considered hypersensitivity pneumonitis with positive serology (HPAbs^+^) as positivity of at least one of the following antibodies: antinuclear antibodies (ANAs) with a specific pattern of connective tissue disease of any kind (cytoplasmic, nucleolar, centromere); ANA with homogeneous pattern, fine or coarse mottle; rheumatoid factor three or more times the upper normal limit (20 IU·mL^−1^); anti-cyclic citrullinated peptide ≥20 RU·mL^−1^ and/or at least one antibody in the autoimmunity profiles for Sjögren\'s syndrome (anti-Ro (SSA), anti-La (SSB)). These autoantibodies were analysed in all the patients. Additionally, autoantibodies associated with systemic sclerosis (anti-Scl-70), vasculitis (anti-neutrophil cytoplasmic antibody (ANCA)) and anti-DNA were examined in 88% of the HPAbs^+^ and 55% of the HPAbs^−^. No patient met classification criteria for connective tissue diseases according to the American College of Rheumatology/European League Against Rheumatism \[[@C15]--[@C17]\].

The patients were classified according to the presence of autoantibodies present in serum (HPAbs^+^ *versus* HPAbs^−^) ([table 1](#TB1){ref-type="table"}).

###### 

Clinical and demographic characteristics in hypersensitivity pneumonitis subgroups

                                                      **Subjects**    **HPAbs^+^**     **Subjects**    **HPAbs^−^**    **p-value**
  -------------------------------------------------- -------------- ----------------- -------------- ----------------- -------------
  **Age years**                                            60             53±9             110             53±12       0.59
  **Female**                                               60            52 (86)           110            89 (81)      0.39
  **Duration of symptoms before diagnosis months**         60          25 (4--20)          110          27 (2--120)    0.30
  **Former smokers**                                       60            14 (23)           110            26 (24)      0.96
  **Exposure to birds**                                    60            47 (78)           110            91 (83)      0.53
  **Diabetes mellitus**                                    60            11 (18)           110            16 (15)      0.51
  **Systemic hypertension**                                60            9 (15)            110            22 (20)      0.53
  **Dead**                                                 54            12 (20)           108             9 (8)       0.02
  **Antibodies against avian antigens**                    60            59 (94)           110            57 (53)      \<0.0001
  **Unidentified antigen**                                 60             4 (6)            110            50 (47)      \<0.0001
  **HRCT chronic pattern**                                 60            48 (80)           110            59 (54)      \<0.001
  **C-reactive protein mg·dL**^−1^                         60        0.9 (0.02--7.1)       110        0.7 (0.01--3.9)  0.95
  **BAL^\#^ lymphocytosis**                                49             49±19             87             46±25       0.17
  **FVC % pred**                                           60            57.8±18           106            53.8±20      0.20
  ***D*~LCO~ % pred**                                      49             46±22             85             51±21       0.24
  **6MWT m**                                               42            333±168            71            333±116      0.21
  ***P*~O~2~~^¶^** **mmHg**                                42             51±8              71             50±13       0.90
  **PAP**^§^ **mmHg**                                      47             39±14             69             38±14       0.40

Data are presented as n, mean±[sd,]{.smallcaps} n [(%)]{.smallcaps} or median (range), unless otherwise stated. HPAbs^+^/HPAbs**^−^**: hypersensitivity pneumonitis with and without autoantibodies, respectively; HRCT: high-resolution computed tomography; BAL: bronchoalveolar lavage; FVC: forced vital capacity; *D*~LCO~: diffusing capacity of the lung for carbon monoxide; 6MWT: 6-min walk test; *P*~O~2~~: oxygen tension; PAP: pulmonary artery pressure. ^\#^: performed in 81% of the HPAbs^+^ patients and 79% of the HPAbs^−^ patients; ^¶^: measured in 42 HPAbs^+^ patients and 71 HPAbs^−^ patients; **^§^**: measured by echocardiography in 47 HPAbs^+^ patients and 69 HPAbs^−^ patients.

Ethics statement {#s2b}
----------------

This study was approved by the institutional committee for science and ethics of the Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas (INER; Mexico City, Mexico) (approbation codes: B20-15 and C60-17).

Genomic DNA isolation {#s2c}
---------------------

Peripheral blood (7 mL) was obtained by venipuncture and was collected in a tube with EDTA as an anticoagulant for subsequent DNA extraction. Samples were obtained at the time of diagnosis, and patients were not receiving corticosteroids or immunosuppressive drugs.

The blood samples were handled in the HLA laboratory of INER to obtain genomic DNA employing a commercial kit (BDtract Genomic DNA Isolation Kit; Maxim Biotech, San Francisco, CA, USA). The DNA was quantified by ultraviolet spectrophotometry using a NanoDrop 2000 device (Thermo Scientific, Waltham, MA, USA). Contamination with organic compounds and proteins was defined by measuring the ratio absorbance at 280 nm and 260 nm. Samples were considered of good quality when the ratio was ∼1.8.

HLA class II molecular typing {#s2d}
-----------------------------

Molecular typing for DRB loci and *DQB1* locus was done using a PCR sequence-specific primers (PCR-SSP) technique using Micro SSP™ HLA DNA Typing Trays (One Lambda, Canoga Park, CA, USA). Unlike other PCR-based methods, the SSP methodology employed discriminates between the different alleles during the PCR process. The amplified DNA fragments are separated by agarose gel electrophoresis and visualised by staining and exposure to ultraviolet light. The interpretation of PCR-SSP results is based on the presence or absence of a specific amplified DNA fragment. Since amplification during the PCR reaction may be adversely affected by various factors such as pipetting errors, poor DNA quality and presence of inhibitors, an internal control primer pair was included in every PCR reaction. The control primer pair amplifies a conserved region of the human β-globin gene, which is present in all human DNA samples and is used to verify the integrity of the PCR reaction.

Initially, HLA-DRB typing was performed by low-resolution modality, which includes *DRB1*, *DRB3*, *DRB4* and *DRB5* alleles in 24 independent reactions. The DRB loci allele group covers *DRB1\*01*, \*03, \*04, \*07, \*08, \*11, \*12, \*13, \*14, \*15 and \*16 as well as *DRB3\*02*, *DRB3\*03*, *DRB4\*01* and *DRB5\*01* specificities (DR51, DR52 and DR53 serological equivalents). High resolution for *HLA-DRB1\*03* was performed with an additional panel of 16 primer pairs to establish allele discrimination. For *HLA-DQB1* typing, eight primer pairs were used, while the *HLA-DQB1* high-resolution kit used to achieve *DQB1* amplification, which includes 55 alleles for DQ6, DQ3, DQ4, DQ5 and DQ2.

All amplifications were performed using the Kapa Taq HotStart PCR kit (Kapa Biosystems, Cape Town, South Africa). PCR-SSP products were electrophoresed in 3% agarose gels stained using MIDORI Green Advanced DNA Stain (Nippon Genetics Europe, Dueren, Germany). Interpretation of typing results was made using the assistance of the HLA Fusion Software *versus* 4.3 (One Lambda).

Statistical analysis {#s2e}
--------------------

The statistics programme SPSS (version 21; SPSS, Chicago, IL, USA) was used to describe the study population and determine the median, minimum, and maximum values for each variable and compared using a Mann--Whitney U-test. Continuous variables were reported as mean±[sd]{.smallcaps} and analysed using a t-test. Categorical variables were reported as counts and percentages and contrasted using Fisher\'s exact test.

Allele and haplotype frequencies of HLA were determined by direct counting. The observed and expected HLA class II alleles (each locus) tested for Hardy--Weinberg equilibrium using a conventional Fisher\'s exact test. The associations were evaluated by Fisher\'s exact two-tailed test, with a statistical significance value of p\<0.05. Bonferroni correction was performed considering the 20 alleles identified in both loci and the 22 haplotypes found in the whole population. Odds ratios and 95% confidence intervals were calculated using 2×2 contingency tables comparing both groups by alleles and haplotypes reported using the Epi Info v4.0.1 \[[@C18]\]. Finally, the haplotypes were constructed employing Arlequin v3.1 software \[[@C19]\] using the maximum likelihood method, with an iterative expectation maximisation algorithm.

To evaluate the strength of association between mortality and the risk allele, we first estimated a crude odds ratio (cOR) using univariate regression analysis; the p-value was estimated with the Wald test, and then we estimated an adjusted odds ratio (aOR) with a multivariate logistic regression analysis that includes only variables with p\<0.05, due to the small sample size. No imputation procedures were performed to handle missing data.

Results {#s3}
=======

Out of 298 patients registered in the hypersensitivity pneumonitis cohort, 93 did not have enough inclusion data for the study, including lack of autoantibodies results (before 2006, ILD patients did not undergo the measurement of autoantibodies routinely), or because our multidisciplinary team did not confirm the diagnosis of hypersensitivity pneumonitis. The other 35 were excluded due to not having enough genomic DNA to perform genotyping. 170 patients with hypersensitivity pneumonitis were included, 60 with circulating autoantibodies (HPAbs^+^) and 110 without (HPAbs^−^) ([figure 1](#F1){ref-type="fig"}). Most HPAbs^+^ patients (89%) were positive for antinuclear antibodies (\>1:320), and occasionally they were also positive for another of the autoantibodies examined (see methods section). 12% (seven patients) were negative for ANA, but showed increased levels of other autoantibodies (*e.g.* rheumatoid factor n=2, ANCA n=2, anti-Ro n=2, anti-La n=1). HPAbs^−^ patients were negative for all examined autoantibodies.

Demographic characteristics {#s3a}
---------------------------

There were no differences between HPAbs^+^ and HPAbs^−^ regarding demographic characteristics, including age, sex and smoking ([table 1](#TB1){ref-type="table"}). Likewise, the comparison of pulmonary function tests between both groups (performed in 49 of 60 HPAbs^+^ patients and 85 of 110 HPAbs patients) showed no differences ([table 1](#TB1){ref-type="table"}). However, HPAbs^+^ patients were more likely to have chronic/fibrotic changes on HRCT than HPAbs^−^. In contrast, the percentage of patients in whom we were unable to identify the antigen was significantly higher in the HPAbs^−^ group ([table 1](#TB1){ref-type="table"}).

During the 1-year follow-up, six HPAbs^+^ patients and two HPAbs^−^ patients were lost. 12% of the entire cohort died, with a significantly higher proportion in the HPAbs^+^ group (20% *versus* 8%, p=0.02).

HLA class II alleles and haplotypes {#s3b}
-----------------------------------

No statistically significant differences were found in the population stratification based on the region of origin between cases and controls. The HLA allele pairs of each locus from both groups satisfied Hardy--Weinberg equilibrium (p\>0.05), accounting for common alleles producing common genotypes, *i.e.* both heterozygous (*e.g. DQB1\*02:01*, *DQB1\*05:01*) and homozygous (*e.g. DQB1\*03:02*) pairs.

The distributions of *DRB1* and *DQB1* alleles are listed in [tables 2](#TB2){ref-type="table"} and [3](#TB3){ref-type="table"}. 10 *HLA-DRB1* alleles were identified in the HPAbs^+^ group, seven of them with an allele frequency \>5%, and the most common were *DRB1\*08* (allele frequency 20.00) and *DRB1\*04* (allele frequency 17.50). A marked increase in the frequency of *HLA-DRB1\*03* was identified in the HPAbs^+^ group (10.8% *versus* 0.45%; OR 30.14, 95% CI 3.83--237.1; p=1.65×10^-4^ after Bonferroni\'s correction for all alleles (20 identified in both loci). All *DRB1\*03* subjects were *DRB1\*03:01* in the high-resolution subtyping analysis. The alleles in the *DRB3* and *DRB4* genes were not found in HPAbs^+^ patients nor in HPAbs^−^ patients, while *DRB5* alleles were identified in few patients without statistical differences.

###### 

Frequencies of human leukocyte antigen (HLA)-DRB1 alleles in patients with hypersensitivity pneumonitis with and without autoantibodies (HPAbs^+^ and HPAbs^−^, respectively)

                  **Hypersensitivity pneumonitis**  **HPAbs^+^**    **HPAbs^−^**  **p-value**    **OR (95% CI)**                           
  -------------- ---------------------------------- -------------- -------------- ------------- ----------------- -------- --------------- ---------------------
  **Patients**                  170                 60                  110                                                                
  **\*01**                       17                 5.000                5        4.167                12         5.455    0.79            0.74 (0.24--2.21)
  **\*03:01**                    14                 4.118                13       10.833                1         0.455    1.65×10^-4\#^   30.14 (3.83--237.1)
  **\*04**                       70                 20.588               21       17.500               49         22.273   0.25            0.67 (0.34--1.28)
  **\*07**                       22                 6.471                9        7.500                13         5.909    0.63            1.31 (0.52--3.28)
  **\*08**                       71                 20.882               24       20.000               47         21.364   0.74            0.89 (0.47--1.69)
  **\*09**                       4                  1.176                ND                             4         1.818                    
  **\*10**                       5                  1.471                ND                             5         2.273                    
  **\*11**                       24                 7.059                6        5.000                18         8.182    0.35            0.56 (0.21--1.51)
  **\*12**                       2                  0.588                ND                             2         0.909                    
  **\*13**                       23                 6.765                10       8.333                13         5.909    0.48            1.49 (0.61--3.64)
  **\*14**                       59                 17.353               18       15.000               41         18.636   0.4             0.72 (0.36--1.41)
  **\*15**                       14                 4.118                8        6.667                 6         2.727    0.08            2.66 (0.87--8.08)
  **\*16**                       15                 4.412                6        5.000                 9         4.091    0.77            1.24 (0.42--3.68)

Data are presented as n, unless otherwise stated. AF: allele frequency; ND: not detected. ^\#^: p-value after Bonferroni\'s correction for the total alleles (n=20) identified in both loci. The comparison was made between HPAbs^+^ *versus* HPAbs^−^ groups.

###### 

Frequencies of human leukocyte antigen (HLA)-DQB1 alleles in patients with hypersensitivity pneumonitis with and without autoantibodies (HPAbs^+^ and HPAbs^−^, respectively)

                  **Hypersensitivity pneumonitis**   **HPAbs^+^**   **HPAbs^−^**   **p-value**   **OR (95% CI)**                      
  -------------- ---------------------------------- -------------- -------------- ------------- ----------------- -------- ---------- -------------------
  **Patients**                  170                       60            110                                                           
  **02:01**                      32                     9.412            18          15.000            14          6.364    0.14^\#^   2.93 (1.33--6.45)
  **03:01**                     115                     33.824           36          30.000            79          35.909     0.12     0.58 (0.30--1.14)
  **03:02**                      68                     20.000           19          15.833            49          22.273     0.14     0.57 (0.29--1.11)
  **03:03**                      4                      1.176            ND                             4          1.818              
  **04:02**                      72                     21.176           25          20.833            47          21.364      1       0.95 (0.50--1.81)
  **05:01**                      24                     7.059            7            5.833            17          7.727      0.64     0.72 (0.28--1.85)
  **06:01**                      25                     7.353            15          12.500            10          4.545    0.12^\#^   3.33 (1.39--7.98)

Data are presented as n, unless otherwise stated. AF: allele frequency; ND: not detected. ^\#^: p-value after Bonferroni\'s correction for the total alleles (n=20) identified in both loci. The comparison was made between HPAbs^+^ *versus* HPAbs^−^ groups.

Seven alleles were recognised at the *HLA-DQB1* locus, among them, *DQB1\*03:01*, *DQB1\*03:02* and *DQB1\*04:02* were the most frequent in both groups. A higher frequency of the allele *DQB1\*02:01* (allele frequency 15.00) was detected in the HPAbs^+^ group compared with HPAbs^−^ (15.0% *versus* 6.364%, p=0.007; OR 2.93, 95% CI 1.33--6.45); however, this association was lost after Bonferroni\'s correction (p=0.14). The frequency of the *HLA-DQB1\*06:01* allele was also more than two-fold higher in the HPAbs^+^ group (12.5% *versus* 4.5%, p=0.006; OR 3.33, 95% CI 1.39--7.98), but Bonferroni\'s correction revealed that this difference was not significant either (p=0.12).

In addition, we compared the haplotype frequency of the *DRB1*-*DQB1* loci. As shown in [table 4](#TB4){ref-type="table"}, 22 haplotypes were identified in the whole hypersensitivity pneumonitis group; interestingly, in the HPAbs^+^ group (n=60) there are 19 haplotypes, while in the HPAbs^−^ group (n=110) only 14 haplotypes were determined (19 out of 22 *versus* 14 out of 22, p=0.08).

###### 

Human leukocyte antigen (HLA)-class II haplotypes (*DRB1\*-DQB1\**) in patients with hypersensitivity pneumonitis with and without autoantibodies (HPAbs^+^ and HPAbs^−^, respectively)

                     **Hypersensitivity pneumonitis**   **HPAbs^+^**   **HPAbs^−^**   **p-value**   **OR (95% CI)**                        
  ----------------- ---------------------------------- -------------- -------------- ------------- ----------------- -------- ------------ ---------------------
  **Patients**                     170                       60            110                                                             
  **01-03:01**                      1                      0.294            1            0.833            ND                               
  **01-05:01**                      16                     4.706            4            3.333            12          5.455       0.42       0.58 (0.17--1.89)
  **03:01-02:01**                   10                     2.941            9            7.500             1          0.455    0.0088^\#^   19.23 (2.37--155.9)
  **03:01-03:01**                   1                      0.294            1            0.833            ND                               
  **03:01-06:01**                   3                      0.882            3            2.500            ND                               
  **04-03:01**                      1                      0.294            1            0.833            ND                               
  **04-03:02**                      68                     20.000           19          15.833            49          22.273      0.14       0.57 (0.29--1.11)
  **04-04:02**                      1                      0.294            1            0.833            ND          0.000                
  **07-02:01**                      22                     6.471            9            7.500            13          5.909       0.63       1.31 (0.52--3.28)
  **08-04:02**                      71                     20.882           24          20.000            47          21.364      0.74       0.89 (0.47--1.69)
  **09-03:03**                      4                      1.176            ND                             4          1.818                
  **10-05:01**                      5                      1.471            ND                             5          2.273                
  **11-03:01**                      16                     4.706            2            1.667            14          6.364       0.05       0.23 (0.05--1.07)
  **11-06:01**                      8                      2.353            4            3.333             4          1.818       0.45       1.89 (0.45--7.85)
  **12-03:01**                      2                      0.588            ND                             2          0.909                
  **13-03:01**                      18                     5.294            5            4.167            13          5.909       0.6        0.67 (0.22--2.0)
  **13-05:01**                      3                      0.882            3            2.500            ND                               
  **13-06:01**                      2                      0.588            2            1.667            ND                               
  **14-03:01**                      59                     17.353           18          15.000            41          18.636      0.4        0.72 (0.36--1.41)
  **15-03:01**                      2                      0.588            2            1.667            ND                               
  **15-06:01**                      12                     3.529            6            5.000             6          2.727       0.34       1.92 (0.59--6.25)
  **16-03:01**                      15                     4.412            6            5.000             9          4.091       0.77       1.24 (0.42--3.68)

Data are presented as n, unless otherwise stated. HF: haplotype frequency; ND: not detected. ^\#^: p-value after Bonferroni correction for the total haplotypes (n=22) identified. The comparison was made between HPAbs^+^ *versus* HPAbs^−^ groups.

We observed a significant higher frequency of the haplotype *DRB1\*03:01*-*DQB1\*02:01* in patients with HPAbs^+^ (7.5% *versus* 0.45%; OR 19.23, 95% CI 2.37--155.9; p=0.0088 after Bonferroni\'s correction (applying the 22 haplotypes identified in the whole population)).

Logistic regression {#s3c}
-------------------

To evaluate the strength of the association between mortality and the risk allele, we estimated the cOR using univariate logistic regression analysis of mortality. The risk allele *HLA-DRB1\*03:01* was associated to mortality (cOR 4.5, 95% CI 1.19--16.9; p=0.026). To adjust for confounding, we performed three multivariate logistic regression models ([table 5](#TB5){ref-type="table"}). In model 1, we included the four variables that showed significant association with mortality by univariate analysis: *HLA-DRB1\*03:01*, *D*~LCO~, C-reactive protein (CRP) and HPAbs^+^. We found that *D*~LCO~ and CRP remained significant. In model 2 when we excluded HPAbs^+^, the allele *HLA-DRB1\*03:01* was strongly associated with mortality (aOR 5.9, 95% CI 1.05--33.0; p=0.043). By contrast, when we excluded the allele *HLA-DRB1\*03:01*, HPAbs^+^ lost significance, supporting the strong association with the risk allele. Importantly, *HLA-DRB1\*03:01* and HPAbs^+^ were strongly associated (OR 9.52, 95% CI 1.85--92), indicating collinearity between these two variables.

###### 

Univariate analysis adjusting the risk allele (DRB1\*03:01) by diffusing capacity of the lung for carbon monoxide (*D*~LCO~) and C-reactive protein (CRP)

                                          **Nonsurvivors**      **Survivors**     **cOR (95% CI)**    **p-value**   **Model 1 aOR (95% CI)**   **p-value**   **Model 2 aOR (95% CI)**   **p-value**   **Model 3 aOR (95% CI)**   **p-value**
  -------------------------------------- ------------------- ------------------- ------------------- ------------- -------------------------- ------------- -------------------------- ------------- -------------------------- -------------
  **Patients**^\#^                               21                  141                                                                                                                                                        
  **Age at baseline evaluation years**        52.8±9.9            52.6±11.3       1.0 (0.96--1.04)       0.94                                                                                                                   
  **Male**                                     6 (29)              22 (16)        2.1 (0.75 --6.10)      0.15                                                                                                                   
  **DRB1\*03:01**                              4 (19)               7 (5)         4.5 (1.19--16.90)      0.026         3.9 (0.69--24.83)          0.14          5.9 (1.05--33.05)          0.043                                
  **Current smokers**                          4 (19)              33 (24)        0.7 (0.23--2.40)       0.62                                                                                                                   
  **Arterial hypertension**                    3 (14)              26 (20)        0.6 (0.18--2.40)       0.54                                                                                                                   
  **Diabetes mellitus**                        3 (14)              20 (15)        0.9 (0.25--3.40)       0.91                                                                                                                   
  **Baseline FVC % pred**                    48 (32--66)         53 (41--73)      0.9 (0.96--1.01)       0.27                                                                                                                   
  **Baseline *D*~LCO~ % pred**              26.5 (20--47)       48.5 (37--64)     0.9 (0.92--0.98)       0.006         0.94 (0.91--0.98)          0.008         0.94 (0.91--0.98)          0.007         0.94 (0.91--0.98)          0.006
  ***P*~O~2~~ mmHg**                          50.9±13.1           50.8±11.0       1.0 (0.95--1.04)       0.99                                                                                                                   
  ***P*~CO~2~~ mmHg**                     33.7 (30.8--36.0)    35 (32.0--39.9)    0.9 (0.85--1.02)       0.13                                                                                                                   
  **PAP**^¶^ **mmHg**                        42 (31--50)         35 (25--45)      1.0 (0.99--1.06)       0.09                                                                                                                   
  **6MWT m**                               333 (220--400)      350 (245--434)     0.9 (0.98--1.00)       0.48                                                                                                                   
  **CRP mg·dL**^−1^                       0.52 (0.37--1.16)   0.43 (0.23--0.84)   1.6 (1.02--2.55)       0.037         2.09 (1.13--3.86)          0.02            2.2 (1.2--3.9)           0.01           2.03 (1.12--3.6)          0.02
  **BAL lymphocytosis %**                    40 (33--54)         47 (30--62)      0.9 (0.96--1.01)       0.36                                                                                                                   
  **HRCT chronic pattern**                     13 (62)             91 (61)        1.03 (0.4--2.65)       0.94                                                                                                                   
  **HPAbs^+^**                                 12 (57)             42 (30)        3.14 (1.23--8.01)      0.02          2.9 (0.83--10.19)          0.09                                                   3.08 (0.88--10.7)          0.076

Data are presented as n, mean±[sd]{.smallcaps}, n (%) or median (range), unless otherwise stated. The crude odds ratio (cOR) of the strength of association of *D*~LCO~ with mortality was estimated with the data of 118 patients. The multivariate logistic regression model was obtained with the data of 103 patients, the goodness of fit of the model is p=0.69, and the area under receiver operating characteristic curve=0.82. HLA DRB1\*03 and HP Abs^+^ were strongly associated (OR 9.52, 95% CI 1.85--92.0), suggesting collinearity between these two variables in model 1. aOR: adjusted odds ratio; FVC: forced vital capacity; *P*~O~2~~: oxygen tension; *P*~CO~2~~: carbon dioxide tension; PAP: pulmonary artery pressure; 6MWT: 6-min walk test; BAL: bronchoalveolar lavage; HRCT: high-resolution computed tomography; HPAbs^+^: hypersensitivity pneumonitis with and without autoantibodies. ^\#^: survival was obtained in 162 out of the 170 patients; ^¶^: measured by echocardiography.

The multivariate logistic regression model was obtained with the data of 103 patients, the goodness of fit of model 2 is p=0.69, and the area under receiver operating characteristic curve=0.82 ([table 5](#TB5){ref-type="table"}).

Discussion {#s4}
==========

Studies about hypersensitivity pneumonitis genetic susceptibility are limited, but HLA class II genes have been identified as critical factors that contribute to disease development \[[@C8], [@C9], [@C20]\].

In the past few years, a growing body of evidence indicates that a subgroup of patients with hypersensitivity pneumonitis develop serum or even clinical features of autoimmunity, although the underlying mechanisms are still unknown. Moreover, except for higher mortality, this "phenotype" has not been characterised.

Similarly, in recent years a subset of patients has been described, who have idiopathic interstitial pneumonia (IIP) and autoimmune features (IPAF), who do not meet the criteria for a connective tissue disease (CTD) but have at least one sign or symptom suggestive of a CTD and at least one serological test reflective of an autoimmune process \[[@C21]\]. These patients have been better characterised, and some studies also suggest that patients who met the IPAF criteria had a significantly worse survival than those with IIP without autoimmune features \[[@C22]\], although substantial variability in outcome has been reported \[[@C23]\]. As in hypersensitivity pneumonitis, the mechanisms and genetic susceptibility triggering the autoimmune process is unknown.

In this study, we found that approximately a third of the patients with hypersensitivity pneumonitis may present autoantibodies. This proportion is higher than reported by A[degunsoye]{.smallcaps} *et al.* \[[@C11]\], to our knowledge the only study to have shown this association, although the reasons are currently unknown.

In this study, we aimed to identify putative genetic factors associated with the HLA class II system that may increase the risk of developing autoimmune features in patients with hypersensitivity pneumonitis. Our results revealed, for the first time, some of the genetic alleles conferring risk of developing autoantibodies in these patients. Thus, a significant increase in the frequency of the *HLA-DRB1\*03:01* allele as well as the haplotype *DRB1\*03:01-DQB1\*02:01* was observed in the group of patients with autoantibodies compared with patients without them.

Interestingly, these alleles have been described in the formation of autoantibodies in classic and rare autoimmune disorders. For example, alleles *HLA-DRB1\*03:01* and *DQB1\*06:01* are associated with the development of autoantibodies in systemic lupus erythematosus \[[@C24], [@C25]\]. Likewise, the presence of anti-Jo-1 or anti-PM-Scl antibodies was found to be strongly associated with *HLA-DRB1\*03:01* and *DQA1\*05:01* alleles in a cohort of patients with adult and juvenile myositis \[[@C26]--[@C28]\]. The *DQB1\*02:01* allele is linked genetically to *DQA1\*05:01* and is classically described in coeliac disease, type 1 diabetes and other autoimmune disorders \[[@C29]\].

Haplotype analysis revealed a significant increase in the frequency of *HLA-DRB1\*03:01-DQB1\*02:01*, commonly observed in the European population \[[@C30]\] and associated with several autoimmune disorders, such as primary Sjögren\'s syndrome with autoantibody production \[[@C31]\]. This haplotype contains two main alleles that are part of 8.1 ancestral haplotype. The ancestral haplotype is an exceptionally long (more than four megabases) conserved combination of alleles: *HLA-A1*, *Cw7*, *B8*, *TNFAB\*a2b3*, TNFN\*S, *C2\*C*, Bf\*s, *C4A\*Q0*, *C4B\*1*, *DRB1\*03:01*, *DRB3\*01:01*, *DQA1\*05:01* and *DQB1\*02:01*. It is accepted as the most critical immunological determinant conferring risk to several autoimmune diseases \[[@C10]\]. Moreover, even healthy carriers of this haplotype show high values of autoantibodies, blood-activated T-cells and blood immune complexes. Therefore, the 8.1 ancestral haplotype enhances immune dysfunctions and autoimmune disorders, and our results suggest that it may also contribute to the development of autoimmunity in hypersensitivity pneumonitis.

Hypersensitivity pneumonitis is a complex disease, where the interaction of environmental and genetic factors influences the development of the disease and the phenotype, *e.g.* fibrotic or nonfibrotic disease \[[@C4]\]. For example, it has been demonstrated that the minor allele frequency of *MUC5B* rs35705950 is higher in patients with chronic hypersensitivity pneumonitis than in healthy controls, and more importantly, that the extent of radiographic fibrosis is associated with this common variant \[[@C32]\].

Our findings suggest that the presence of specific alleles and haplotypes of the HLA system may lead to the development of autoimmune features, modifying the course and outcome of hypersensitivity pneumonitis. Moreover, to carry the risk allele, *HLA-DRB1\*03:01* was associated with reduced survival. Interestingly, immune dysfunctions associated with the 8.1 ancestral haplotype appear to be a factor to early morbidity and mortality in older females \[[@C33]\]; females were markedly more frequent in our hypersensitivity pneumonitis cohort.

In addition, we found that mortality in the group of HPAbs^+^ was higher than in the group without autoantibodies, coinciding with a previous study in which the presence of autoimmunity was found to be associated with poor prognosis \[[@C11]\]. However, after adjusting by the allele *HLA-DRB1\*03:01*, the presence of autoantibodies lost significance. Surprisingly, mortality did not show differences between chronic fibrotic and nonfibrotic hypersensitivity pneumonitis patients, probably because of the short time of follow-up and the small sample size.

Our research has some limitations, including the relatively small sample size. Besides, we excluded patients with hypersensitivity pneumonitis and confirmed connective tissue disease or a history of inflammatory disorders.

Further studies are needed to validate these findings and to determine the molecular mechanisms of the underlying autoimmune process in patients with hypersensitivity pneumonitis.

Conclusion {#s4a}
----------

In patients with hypersensitivity pneumonitis, the allele *HLA-DRB1\*03:01* and the haplotype *DRB1\*03:01-DQB1\*02:01*, part of the 8.1 ancestral haplotype, a major genetic determinant of autoimmune diseases, are associated with the presence of autoantibodies. HLA-DRB1\*03:01 also increases the risk of mortality in patients with hypersensitivity pneumonitis.
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